The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Androgen receptor pathway inhibitors were shown to better treat patients with metastatic castration-resistant prostate cancer and improved survival. In patients with metastatic castration-resistant ...

In patients with prostate cancer, androgen receptor pathway inhibitors (ARPIs) extended the median time to no longer clinically benefitting (NLCB) to 11.1 months compared with the 6.9 months seen with ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

A secondary analysis of the phase III VISION trial presented at this year's American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium found that adding androgen receptor pathway ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...

Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who ...